This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Dormandy, J. Search for Related Content Social Bookmarking                         What's this?

The need for outcome studies in type 2 diabetes

Clinical Research Centre, Vascular Division,1st Floor Ingleby House, St Georges Hospital Medical School, Blackshaw Road, University of London, London, SW17 0QT, UK, dormandyjohn{at}aol.com

Outcome studies use primary end points such as overall mortality or major morbidity to demonstrate that treatments deliver meaningful clinical benefits. Historically it was thought that most of the cardiovascular morbidity due to diabetes was related to microvascular disease, providing a marker for macrovascular disease. In diabetes an outcome study would measure all-cause death, cardiac death and cardiovascular morbidity (end points related to macrovascular disease), whereas conventional trials in diabetes have used surrogate end points, such as blood pressure, microvascular disease (retinopathy, nephropathy) or glycaemic control, which may not predict clinical benefits in the prevention of macrovascular end points. Although outcome trials are increasingly required by regulatory or funding agencies, few have been performed in diabetes; most data have come from trials with surrogate end points or subgroup analyses of cardiovascular outcome trials. Methodological constraints, particularly the large patient populations and long follow-up required, partly explain the lack of outcome studies in diabetes.

The PROspective pioglitAzone Clinical Trial In macroVascular Events (PROactive) is a macrovascular outcome study in patients with type 2 diabetes. It will involve approximately 4,000 patients who will receive pioglitazone or placebo in addition to their existing therapy. Principal end points will be all-cause mortality and severe disability due to macrovascular complications. PROactive should provide important data on the impact of therapy on the incidence of cardiovascular complications in type 2 diabetes.

Key Words: clinical trials • diabetes • drug therapy • morbidity • mortality • pioglitazone.

References

• Collins R., MacMahon S. Reliable assessment of the effects of treatment on mortality and major morbidity, I: clinical trials. Lancet 2001;357:373-80.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Epstein AE, Bigger JT Jr, Wyse DG, Romhilt DW, Reynolds-Haertle RA, Hallstrom AP Events in the Cardiac Arrhythmia Suppression Trial (CAST): mortality in the entire population enrolled. J Am Coll Cardiol 1991;18:14-19.[Abstract]
• Heeschen C., Hamm CW Difficulties with oral platelet glycoprotein IIb/IIIa receptor antagonists. Lancet 2000;355:330-1.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Drummond MF, O'Brian BJ, Stoddart GL, Torrance GW Methods for the economic evaluation of health care programmes, 2nd Ed. Oxford: Oxford University Press, 1997.
• University Group Diabetes Program. A study of the effects of hypoglycemic agents on vascular complications in patients with adult onset diabetes. II. Mortality results. Diabetes 1970;19(suppl 20):785-830.
• Kilo C., Miller JP, Williamson JR The crux of the UGDP. Spurious results and biologically inappropriate data analysis. Diabetologia 1980;18:179-85.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Seltzer HS A summary of criticisms of the findings and conclusions of the University Group Diabetes Program (UGDP). Diabetes 1972;21:976-9.[Web of Science][Medline] [Order article via Infotrieve]
• UK Prospective Diabetes Study (UKPDS) Group. UK Prospective Diabetes Study (UKPDS). VIII. Study design, progress and performance. Diabetologia 1991;34:877-90.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Turner RC The U.K. Prospective Diabetes Study. A review. Diabetes Care 1998;21(suppl 3):C35-8.
• UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-65.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Nathan DM Some answers, more controversy, from UKPDS. Lancet 1998;352:832-3.[Web of Science][Medline] [Order article via Infotrieve]
• The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-86.[Abstract/Free Full Text]
• Diabetes Atherosclerosis Intervention Study Investigators. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet 2001;357:905-10.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensin receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-60.[Abstract/Free Full Text]
• Brenner BM, Cooper ME, de Zeeuw D. et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-9.[Abstract/Free Full Text]
• The Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349-57.[Abstract/Free Full Text]
• Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE Study and MICRO-HOPE substudy. Lancet 2000;355:253-9.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Freeman DJ, Norrie J., Sattar N. et al. Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation 2001;103:357-62.[Abstract/Free Full Text]
• Khaw K.-T, Wareham N., Luben R., Bingham S., Oakes S., Welch A., Day N. Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of European Prospective Investigation of Cancer and Nutrition (EPIC-Norfolk). BMJ 2001;322:1-6.[Abstract/Free Full Text]
• Antiplatelet Trialists ' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy. I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994;308:81-106.[Abstract/Free Full Text]
• Yusuf S., Collins R., Peto R. et al. Intravenous and intracoronary fibrinolytic therapy in acute myocardial infarction: overview of results on mortality, reinfarction and side-effects from 33 randomized controlled trials. Eur Heart J 1985;6:556-85.[Abstract/Free Full Text]
• Dormandy J., Belcher G., Broos P. et al. Prospective study of 713 below-knee amputations for ischaemia and the effect of a prostacyclin analogue on healing. Br J Surg 1994;81:33-7.[Web of Science][Medline] [Order article via Infotrieve]
• The Coronary Drug Project Research Group. Influence of adherence to treatment and response of cholesterol on mortality in the coronary drug project. N Engl J Med 1980;303:1038-41.[Abstract]

The British Journal of Diabetes & Vascular Disease, Vol. 2, No. 1 suppl, S32-S36 (2002)
DOI: 10.1177/14746514020020010801


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Dormandy, J. Search for Related Content Social Bookmarking                         What's this?